Introduction: Hepatitis E virus (HEV) is an enterically transmitted acute viral hepatitis with the highest incidence in Asia, Africa, the Middle East, and Central America. There are few published data on the epidemiology of the infection in Iran. Hence, this study was carried out to evaluate anti-HEV seroprevalence in Isfahan Province, Iran. Methods: In 2005, a cross-sectional study of 816 subjects over 6 years of age from urban and rural areas of Isfahan Province, selected using the multistage cluster sampling method, was undertaken. Demographic data and blood samples were collected, and anti-HEV antibodies were measured by ELISA method. The Chi-square test was used for statistical analysis and p < 0.05 was considered significant. Results: Of the study subjects, 428 were female (52.5%) and 388 were male (47.5%). The overall anti-HEV seroprevalence rate was 3.8%. There was no significant difference in HEV seropositivity between the subjects grouped according to gender (4.2% in females and 3.4% in males, p = 0.78), household number ( p = 0.95), and area of residence (2.7% in rural and 4.1% in urban areas, p = 0.09). HEV seroprevalence increased with age from 0.9% in children aged 6-9 years to 8.1% in persons over 50 years old, without statistical differences ( p = 0.08). There were statistical differences in HEV seropositivity in the different regions of Isfahan Province, with the highest prevalence seen in Khomeini Shahr (13.3%; p < 0.001). Conclusion: HEV seroprevalence in Isfahan Province is lower than that previously reported in other parts of Iran and the Middle East area. More studies in other parts of Iran are needed to obtain a prevalence map for creating preventional strategies. #
associated with high mortality rates in pregnant women (from about 20% to 30%), especially during the third trimester of pregnancy, as a result of fulminant liver disease. 1 Recently, the virus has been reclassified in the genus Hepevirus of the family Hepeviridae. 2 HEV is spread by focally contaminated water and by blood transfusion in endemic areas, but personto-person transmission is uncommon. A vaccine against HEV is not yet commercially available, and travelers to endemic areas should engage in practices that may prevent infection such as avoiding drinking water of unknown purity and eating uncooked shellfish, fruits, or vegetables. [3] [4] [5] High attack rates are found in adults between 15 and 40 years of age. Secondary attack rates in susceptible household contacts are low due to the lack of person-to-person transmission, and range from 0.7% to 2.2%. 6 The prevalence of antibodies to HEV (anti-HEV) has been described for several populations, with levels as high as 40% in India. 7 Investigations show that HEV-mediated hepatitis is a serious public health problem in developing countries of Asia, the Middle East, and Africa, as well as in Mexico. 2 In much of Asia, HEV is the single most frequent cause of acute hepatitis in adults, and in parts of the Middle East and North Africa it is second only to hepatitis B. HEV endemicity in the world is currently under investigation, and a more complete picture of the worldwide distribution and seroprevalence of HEV infections is emerging. 8 The results of limited epidemiological studies in Iran have implied regional differences in anti-HEV antibody seroprevalence rates and there are no documents on this subject in the central and south areas of our country. Hence, the aim of this study was to identify anti-HEV prevalence in the human population of Isfahan Province, as a tourist area in Iran, and its relationship with age, gender, education, household numbers, and region, to support the implementation of future strategies to improve national and international surveillance.
Methods and materials
In a cross-sectional survey in 2005, 816 samples from the population of Isfahan Province aged over 6 years were collected using the multistage cluster sampling method. Isfahan is a large province in the center of Iran with a high level of tourism, and about 79.3% of residents live in the urban areas. This province is located southeast of Tehran and consists of 19 districts. Isfahan City is the center of Isfahan Province (Figures 1 and 2 ).
There were 41 clusters in each of 20 samples, from which, according to the proportion of the population in rural and urban areas, nine rural and 11 urban clusters were selected. From each selected family, one subject in each age group was chosen randomly to be enrolled into the study. There were six age groups: 6-9, 10-19, 20-29, 30-39, 40-49, and over 50 years.
The subjects were given detailed information about the study, and written consent was obtained. They were asked about their age, gender, area of residence, number in the household, and education. A 5 ml venous blood sample was drawn from each subject and transferred to the healthcare center in less than 3 hours. Whole blood was centrifuged at 3000 rpm for 15 min and after serum isolation, was frozen by Alicot method. Samples were then transferred to the Isfahan Infectious Diseases and Tropical Medicine Research Center by cold chain method and were stored at À70 8C until the anti-HEV antibody assay. The presence of anti-HEV in human sera was determined using a commercial HEV ELISA kit (Dia-pro from Milan, Italy) according to the manufacturer's instructions.
Collected data were coded, analyzed, and computed using the Statistical Package for Social Sciences (SPSS) version 13. Descriptive statistics and Chi-square tests were used in the statistical analysis, and a p-value of 0.05 was considered significant.
The study was approved by the Ethics Committee of the Research Department of Isfahan University of Medical Sciences.
Results
Of the study subjects, 428 were female (52.5%) and 388 were male (47.5%); 77.7% lived in urban areas and 22.3% in rural areas. The overall anti-HEV seroprevalence rate was 3.8%. There was no significant difference between the subjects grouped according to gender (4.2% in females and 3.4% in males, p = 0.78) and household number ( p = 0.95). Seroprevalence increased with age from 0.9% in children aged 6-9 years to 8.1% in persons over 50 years old, but there were no statistical difference between the age groups ( p = 0.08). No significant differences were detected between the prevalence of anti-HEV antibodies in rural (2.7%) and urban (4.1%) areas ( p = 0.09) ( Table 1 ). There was also no difference in anti-HEV seroprevalence according to educational status ( p = 0.5).
When we compared anti-HEV antibody seroprevalence rates in different regions of Isfahan Province, the highest prevalences were observed in Khomeini Shahr (13.3%) and Mobarekeh (10%) ( Table 2) . 
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Discussion
Although several large outbreaks of hepatitis E have been observed in the Middle East, population-based studies regarding the seroprevalence of this infection in Iran are inadequate. In this community-based survey, anti-HEV seroprevalence in Isfahan Province in 2005 has been estimated at 3.8%. The value obtained is much lower than that of some of our neighbors, e.g., Iraqi-Kurdish refugees (14.8%) 9 and the general population in Pakistan (17.5%), 10 but similar to rates in Ankara, Turkey (3.8%). 11 In Turkey, different results have been obtained in different regions, and range from 2.1% to 12.8%. 1 In other parts of the world, anti-HEV antibody seropositivity has been reported at 3.4% in preschool children in Taiwan, 12 10.5% in Mexicans aged 1 to 29 years, 13 11.9% in the Korean population, 2 and 17.2% in a village (Nile Delta) in Egypt. 14 In developed countries, HEV seroprevalence is lower. For example, it has been reported at 2.6% in Italy, 15 2.8% in Israeli Jews, and 1.8% in Israeli Arabs. 16 There are limited documented studies in Iran. In a study by Alizadeh et al. 17 in Nahavand, Iran in 2002, anti-HEV antibody seroprevalence was 9.6%, and was higher in females and in those aged 30-50 years than in males and the other age groups. In another study, anti-HEV antibodies were detected in blood donors in Tehran, Iran (2004) where the seroprevalence was reported as 7.8%. 18 So, the prevalence of anti-HEV IgG in humans from this current study is much lower than in previous studies in other parts of Iran. Also, in this study there was no statistical relationship between HEV-antibody seropositivity and age, gender, household crowding, or education.
These results are consistent with those of most other studies in the world. 19 However, there were different rates of anti-HEV seropositivity in the different regions of Isfahan Province, which must be considered for future studies to obtain the real risk factors in high prevalence areas and to create preventive strategies.
In conclusion, the prevalence of anti-HEV antibody in the human population living in Isfahan Province is not high. More studies are needed in other areas in Iran to obtain an HEV prevalence map and to limit its transmission.
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